Drug Profile


Alternative Names: AP-26113

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator ARIAD Pharmaceuticals
  • Class Antineoplastics; Diamines; Piperazines; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Epidermal growth factor receptor antagonists; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer
  • No development reported Lymphoma; Neuroblastoma

Most Recent Events

  • 07 Dec 2016 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer presented at the 17th World Conference on Lung Cancer (WCLC-2016)
  • 09 Nov 2016 Efficacy and Adverse events data from a phase I/II trial in Non-small cell lung cancer released by ARIAD Pharmaceuticals
  • 03 Nov 2016 Brigatinib receives priority review status for Non-small cell lung cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top